BNP Paribas Financial Markets
APRE icon

BNP Paribas Financial Markets’s Aprea Therapeutics APRE Stock Holding History

BNP Paribas Financial Markets’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.3K Buy
45,211
+5,394
+14% +$4.5K ﹤0.01% 5036
2026
Q1 		$30.4K Buy
39,817
+12,485
+46% +$9.82K ﹤0.01% 4941
2025
Q4 		$23.3K Buy
27,332
+10,200
+60% +$12.5K ﹤0.01% 4980
2025
Q3 		$25.3K Buy
17,132
+1,700
+11% +$2.8K ﹤0.01% 4850
2025
Q2 		$26.2K Buy
15,432
+1,721
+13% +$2.93K ﹤0.01% 4490
2025
Q1 		$28K Buy
13,711
+700
+5% +$2.19K ﹤0.01% 4448
2024
Q4 		$42.7K Buy
+13,011
New +$43.5K ﹤0.01% 4485
2022
Q4 		– Sell
-3,092
Closed -$40.2K – 4074
2022
Q3 		$40.2K Buy
+3,092
New +$54.9K ﹤0.01% 4017

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets's APRE Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Aprea Therapeutics (APRE) stake by 14% in Q2 2026, buying an estimated $4.5K and bringing the position to 45,211 shares worth $36.3K. The position accounts for ﹤0.01% of the portfolio, ranked #5036.

BNP Paribas Financial Markets first reported a position in APRE in Q3 2022 and has held it in 8 quarters since. The position peaked at $42.7K in Q4 2024. 26 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

  • BNP Paribas Financial Markets held 45,211 shares of Aprea Therapeutics worth $36.3K as of Q2 2026.
  • BNP Paribas Financial Markets bought 5,394 Aprea Therapeutics shares in Q2 2026, an estimated $4.5K.
  • Aprea Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5036 holding.
  • BNP Paribas Financial Markets first reported a position in Aprea Therapeutics in Q3 2022 and has held it in 8 quarters since.
  • BNP Paribas Financial Markets's Aprea Therapeutics position peaked at $42.7K in Q4 2024.
  • 26 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.